US biotech Gilead Sciences (Nasdaq: GILD) has filed a lawsuit with the Russian Supreme Court challenging the decision of the Russian government to issue a license to the domestic drugmaker Pharmsynthez for the manufacture of its original anti-COVID-19 drug remdesivir without its consent, reports The Pharma Letter’s local correspondent.
On December, 31, 2020, Russian Prime Minister Mikhail Mishustin signed a decree giving the right to Pharmsynthez to produce an analogue of Gilead’s Veklury (remdesivir) under the Remdeform brand without permission from Gilead within a one-year period. The Russian firm began producing its generic in February this year.
In the decree, Mr Mishustin refers to the Russian Civil Code, which allows the use of such a mechanism in the interests of national security, while the patent holder will be provided with monetary compensation. The amount of compensation was not disclosed. This was the first time a compulsory license for the production of a drug was issued in Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze